Electromagnetic Field Protection Device Use Impact in Healthy Volunteers

Aging Clinical Trial

Official title:

Clinical and Molecular Impact of In-home Resonance-based Electromagnetic Field Protection Device Usage in Healthy Individuals

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05001646
• Other study ID #: ALT-BS-001
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 2022
• Est. completion date: April 2023

Study information

• Verified date: March 2022
• Source: TruDiagnostic
• Contact: Natalie Amalani
• Phone: 816-377-4651
• Email: natalie[@]blushield-us.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, single group, self-controlled study to evaluate the clinical and molecular impact of continuous in-home resonance-based electromagnetic field (EMF) protection device usage in healthy individuals.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 44
• Est. completion date: April 2023
• Est. primary completion date: January 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

• Any sex, gender orientation, and ethnicity

• Between ages 30 and 70

• Must be willing and able to participate in venipuncture, health history and clinical assessments, passive monitoring (Oura ring), and continuous in-home Blushield device usage

Exclusion Criteria:

• Significant change in diagnosis and/or treatment of major illness or injury within 2 years prior to screening, e.g., diabetes, cancer, cardiovascular disease, psychiatric condition 2. Any ongoing immune system concerns or immunodeficiency disease

• History of any viral illness in preceding year

• Body mass index (BMI) > 35 kg/m2

• Presence of active infection

• Any other illness, disorder, alcohol or chemical dependence that in the opinion of investigators would render study participation unsuitable

• Unable or unwilling to provide required biological sample

• Unable or unwilling to avoid pregnancy during study period

Related Conditions & MeSH terms

• Aging
• Aging Well

Intervention

Device:
• In-home resonance-based electromagnetic field protection device
Participants will have an in-home EMF protection device

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
TruDiagnostic	Blushield USA

References & Publications (3)

Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of Cellular Senescence. Trends Cell Biol. 2018 Jun;28(6):436-453. doi: 10.1016/j.tcb.2018.02.001. Epub 2018 Feb 21. Review. — View Citation

Karipidis K, Mate R, Urban D, Tinker R, Wood A. 5G mobile networks and health-a state-of-the-science review of the research into low-level RF fields above 6 GHz. J Expo Sci Environ Epidemiol. 2021 Jul;31(4):585-605. doi: 10.1038/s41370-021-00297-6. Epub 2021 Mar 16. Review. — View Citation

Kohli J, Wang B, Brandenburg SM, Basisty N, Evangelou K, Varela-Eirin M, Campisi J, Schilling B, Gorgoulis V, Demaria M. Algorithmic assessment of cellular senescence in experimental and clinical specimens. Nat Protoc. 2021 May;16(5):2471-2498. doi: 10.1038/s41596-021-00505-5. Epub 2021 Apr 28. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Epigenetic Testing		Change from baseline to 12 weeks